Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Tarsus Pharmaceuticals Inc (TARS)

Tarsus Pharmaceuticals Inc (TARS)
40.57 x 1 53.00 x 3
Pre-market by (Cboe BZX)
50.65 -0.36 (-0.71%) 03/27/25 [NASDAQ]
40.57 x 1 53.00 x 3
Pre-market 50.60 -0.05 (-0.10%) 06:13 ET
Quote Overview for Thu, Mar 27th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
49.53
Day High
51.33
Open 51.14
Previous Close 51.01 51.01
Volume 1,652,500 1,652,500
Avg Vol 691,045 691,045
Stochastic %K 82.20% 82.20%
Weighted Alpha +46.99 +46.99
5-Day Change +0.74 (+1.48%) +0.74 (+1.48%)
52-Week Range 20.08 - 57.28 20.08 - 57.28
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,943,795
  • Shares Outstanding, K 38,377
  • Annual Sales, $ 182,950 K
  • Annual Income, $ -115,550 K
  • EBIT $ -121 M
  • EBITDA $ -123 M
  • 60-Month Beta 1.05
  • Price/Sales 10.70
  • Price/Cash Flow N/A
  • Price/Book 8.74

Options Overview Details

View History
  • Implied Volatility 52.99% ( +3.04%)
  • Historical Volatility 57.71%
  • IV Percentile 4%
  • IV Rank 9.04%
  • IV High 127.03% on 11/08/24
  • IV Low 45.63% on 05/24/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 20
  • Volume Avg (30-Day) 51
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 916
  • Open Int (30-Day) 1,250

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.78
  • Number of Estimates 5
  • High Estimate -0.65
  • Low Estimate -0.83
  • Prior Year -1.01
  • Growth Rate Est. (year over year) +22.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.30 +22.64%
on 03/04/25
Period Open: 43.55
52.63 -3.76%
on 03/24/25
+7.10 (+16.30%)
since 02/27/25
3-Month
40.41 +25.34%
on 02/25/25
Period Open: 55.00
57.28 -11.57%
on 02/05/25
-4.35 (-7.91%)
since 12/27/24
52-Week
20.08 +152.22%
on 08/05/24
Period Open: 34.57
57.28 -11.57%
on 02/05/25
+16.08 (+46.51%)
since 03/27/24

Most Recent Stories

More News
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering

TARS : 50.65 (-0.71%)
Tarsus Announces Proposed $100.0 Million Public Offering

TARS : 50.65 (-0.71%)
Tarsus to Participate in Upcoming Investor Conference

TARS : 50.65 (-0.71%)
Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements

TARS : 50.65 (-0.71%)
Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025

TARS : 50.65 (-0.71%)
Tarsus to Participate in Upcoming Investor Conferences

TARS : 50.65 (-0.71%)
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care

TARS : 50.65 (-0.71%)
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex

For Immediate ReleaseChicago, IL – December 26, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and...

CDXC : 7.87 (-0.88%)
ADMA : 20.28 (+2.94%)
TARS : 50.65 (-0.71%)
STOK : 7.45 (+0.68%)
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow

The biotech sector witnessed a see-saw performance in 2024. While the year started on a positive note, much of the gains slowed down in the second half of 2024. The downside in the second half was due...

CDXC : 7.87 (-0.88%)
ADMA : 20.28 (+2.94%)
TARS : 50.65 (-0.71%)
STOK : 7.45 (+0.68%)
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements

TARS : 50.65 (-0.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Tarsus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. The company's product candidate consist TP-03 which is in clinical stage. Tarsus Pharmaceuticals Inc. is based...

See More

Key Turning Points

3rd Resistance Point 53.28
2nd Resistance Point 52.30
1st Resistance Point 51.48
Last Price 50.65
1st Support Level 49.68
2nd Support Level 48.70
3rd Support Level 47.88

See More

52-Week High 57.28
Last Price 50.65
Fibonacci 61.8% 43.07
Fibonacci 50% 38.68
Fibonacci 38.2% 34.29
52-Week Low 20.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies